MX2022014784A - Terapias combinadas que comprenden un agente de hipometilacion para el tratamiento del cancer. - Google Patents
Terapias combinadas que comprenden un agente de hipometilacion para el tratamiento del cancer.Info
- Publication number
- MX2022014784A MX2022014784A MX2022014784A MX2022014784A MX2022014784A MX 2022014784 A MX2022014784 A MX 2022014784A MX 2022014784 A MX2022014784 A MX 2022014784A MX 2022014784 A MX2022014784 A MX 2022014784A MX 2022014784 A MX2022014784 A MX 2022014784A
- Authority
- MX
- Mexico
- Prior art keywords
- treating cancer
- combination therapies
- hypomethylation agent
- agent
- hypomethylation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 abstract 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 229960002756 azacitidine Drugs 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 229940075628 hypomethylating agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan métodos para el tratamiento del cáncer (por ejemplo, un cáncer hematológico tal como síndrome mielodisplásico) que comprende administrar un polipéptido (por ejemplo, un polipéptido de fusión) que comprende una variante del dominio D1 de SIRPa y una variante del dominio Fc en combinación con un agente hipometilante (por ejemplo, azacitidina). También se proporcionan kits relacionados.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063033074P | 2020-06-01 | 2020-06-01 | |
US202063106285P | 2020-10-27 | 2020-10-27 | |
US202063109083P | 2020-11-03 | 2020-11-03 | |
US202063114959P | 2020-11-17 | 2020-11-17 | |
US202163145925P | 2021-02-04 | 2021-02-04 | |
PCT/US2021/034967 WO2021247430A1 (en) | 2020-06-01 | 2021-05-28 | Combination therapies comprising a hypomethylation agent for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022014784A true MX2022014784A (es) | 2023-01-16 |
Family
ID=76808133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022014784A MX2022014784A (es) | 2020-06-01 | 2021-05-28 | Terapias combinadas que comprenden un agente de hipometilacion para el tratamiento del cancer. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220401516A1 (es) |
EP (1) | EP4157315A1 (es) |
JP (1) | JP2023528341A (es) |
KR (1) | KR20230018475A (es) |
CN (1) | CN115666620A (es) |
AU (1) | AU2021283083A1 (es) |
CA (1) | CA3178157A1 (es) |
IL (1) | IL298644A (es) |
MX (1) | MX2022014784A (es) |
WO (1) | WO2021247430A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3331902T3 (da) | 2015-08-07 | 2021-07-26 | Alx Oncology Inc | Konstruktioner med et sirp-alpha-domæne eller en variant deraf |
US11613564B2 (en) * | 2019-05-31 | 2023-03-28 | ALX Oncology Inc. | Methods of treating cancer |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2804617T3 (da) | 2012-01-17 | 2020-08-10 | Univ Leland Stanford Junior | Højaffine sirp-alpha-reagenser |
PT3575326T (pt) | 2012-12-17 | 2022-05-30 | Pf Argentum Ip Holdings Llc | Tratamento de células de doença cd47+ com fusões sirp alfa-fc |
CN106535914B (zh) | 2014-08-08 | 2021-08-27 | Alx 肿瘤生物技术公司 | SIRP-α变体构建体及其用途 |
EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
CN106146670B (zh) | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术(上海)有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
WO2016187226A1 (en) | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
DK3331902T3 (da) | 2015-08-07 | 2021-07-26 | Alx Oncology Inc | Konstruktioner med et sirp-alpha-domæne eller en variant deraf |
US20180312600A1 (en) | 2015-10-21 | 2018-11-01 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
BR112018070823A2 (pt) | 2016-04-14 | 2019-02-05 | Ose Immunotherapeutics | anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno. |
US20190091290A1 (en) | 2016-04-15 | 2019-03-28 | Trillium Therapeutics Inc. | Macrophage stimulation in cd47 blockade therapy |
CA3031034A1 (en) | 2016-08-03 | 2018-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy |
JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
EP3534964A4 (en) | 2016-11-03 | 2020-07-15 | Trillium Therapeutics Inc. | IMPROVEMENT OF CD47 BLOCKING THERAPY BY PROTEASOME INHIBITORS |
EP3534965A4 (en) | 2016-11-03 | 2020-06-24 | Trillium Therapeutics Inc. | IMPROVEMENTS IN CD47 BLOCKADERAPY THROUGH HDAC INHIBITORS |
JP7173971B2 (ja) | 2016-12-09 | 2022-11-16 | アレクトル エルエルシー | 抗SIRP-α抗体及びその使用方法 |
JP7179743B2 (ja) | 2017-02-17 | 2022-11-29 | オーエスイー・イミュノセラピューティクス | 抗SIRPg抗体の新規の使用 |
WO2018176132A1 (en) | 2017-03-28 | 2018-10-04 | Trillium Therapeutics Inc. | Cd47 blockade therapy |
CN110650976B (zh) | 2017-04-13 | 2024-04-19 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
CA3063622A1 (en) | 2017-05-16 | 2018-11-22 | Synthon Biopharmaceuticals B.V. | Anti-sirp.alpha. antibodies |
WO2019023347A1 (en) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS |
EP3843772A2 (en) * | 2018-08-31 | 2021-07-07 | ALX Oncology Inc. | Decoy polypeptides |
CN118178645A (zh) * | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
-
2021
- 2021-05-28 IL IL298644A patent/IL298644A/en unknown
- 2021-05-28 CN CN202180039242.XA patent/CN115666620A/zh active Pending
- 2021-05-28 MX MX2022014784A patent/MX2022014784A/es unknown
- 2021-05-28 AU AU2021283083A patent/AU2021283083A1/en active Pending
- 2021-05-28 EP EP21739202.6A patent/EP4157315A1/en active Pending
- 2021-05-28 WO PCT/US2021/034967 patent/WO2021247430A1/en unknown
- 2021-05-28 JP JP2022572558A patent/JP2023528341A/ja active Pending
- 2021-05-28 CA CA3178157A patent/CA3178157A1/en active Pending
- 2021-05-28 US US17/334,151 patent/US20220401516A1/en active Pending
- 2021-05-28 KR KR1020227046227A patent/KR20230018475A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
CA3178157A1 (en) | 2021-12-09 |
EP4157315A1 (en) | 2023-04-05 |
KR20230018475A (ko) | 2023-02-07 |
WO2021247430A1 (en) | 2021-12-09 |
CN115666620A (zh) | 2023-01-31 |
JP2023528341A (ja) | 2023-07-04 |
IL298644A (en) | 2023-01-01 |
AU2021283083A1 (en) | 2022-12-01 |
US20220401516A1 (en) | 2022-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022014784A (es) | Terapias combinadas que comprenden un agente de hipometilacion para el tratamiento del cancer. | |
MX2022006078A (es) | Terapias de combinacion para el tratamiento del cancer. | |
MX2022004370A (es) | Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda. | |
CO2020016559A2 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
AU2018275894A1 (en) | Articles of manufacture and methods for treatment using adoptive cell therapy | |
CL2018003700A1 (es) | Terapias de combinación. | |
Zeidan et al. | Beyond hypomethylating agents failure in patients with myelodysplastic syndromes | |
CO2021016552A2 (es) | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso | |
BR112021017678A2 (pt) | Uso de catequentinibe (anlotinibe) combinando com quimioterapia padrão ou imunoterapia em ordem sequencial para o tratamento de câncer | |
MXPA05005726A (es) | Metodos y composiciones para inducir apoptosis en celulas de cancer. | |
MX2023013259A (es) | Terapias de combinacion para el tratamiento del cancer. | |
AR048819A1 (es) | Metodos sinergicos y composiciones para el tratamiento del cancer | |
AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
BR112015000660A2 (pt) | uso de uma terapia de primeira linha e uma terapia de segunda linha para tratamento de um paciente possuindo uma doença, desordem ou condição associada com uma expressão elevada de um antígeno de tumor, e de uma composição para reduzir ou evitar um efeito adverso associado com a administração de uma célula geneticamente modificada para expressar um car. | |
BR112018076639A2 (pt) | quimioterapias de combinação | |
WO2022051591A3 (en) | Nectin-4 antibodies and uses thereof | |
WO2006076525A3 (en) | Combination cancer therapy with anti-psma antibodies | |
CR20230164A (es) | Compuestos fosfolípidos y usos de estos | |
Liese et al. | Cotreatment with sorafenib and oleanolic acid induces reactive oxygen species-dependent and mitochondrial-mediated apoptotic cell death in hepatocellular carcinoma cells | |
MX2023004032A (es) | Terapias inmuno-oncologicas con conjugados de il-2. | |
FR3096259B1 (fr) | conjugués anticorps-médicament et leur utilisation en thérapie | |
Joudi et al. | Second-line intravesical therapy versus cystectomy for bacille Calmette-Guerin (BCG) failures | |
BR112018070847A2 (pt) | terapias combinadas para tratamento de câncer compreendendo um derivado de bacterioclorofila | |
MX2022013402A (es) | Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y folfiri. | |
MX2019001545A (es) | Composiciones y metodos para tratar cancer con supresion de arginina y agentes de inmuno-oncologia. |